Published on: 07 November 2012
William Charnetski, AstraZeneca
26th IFPMA assembly – IFPMA leadership 2010-2012 – Geneva, October 31, 2012
Resources
Skip to content
- Inventing Medicines and Vaccines
- Strengthening Regulatory Systems
- Ethics and Business Integrity
- Boosting Innovation and Access
- Tackling Global health challenges
African Medicines Agency Biosimilars Biotherapeutic medicines Falsified medicines Import testing Pharmacovigilance Quality, safety, and efficacy Regulatory conferences Regulatory system strengthening / Harmonization Supply chain The Africa Regulatory Network (ARN) The ARN: Le réseau africain de réglementation pharmaceutique
Ageing Antimicrobial resistance Cancer Child and maternal health COVID-19 Diabetes Ebola Falsified medicines HIV/AIDS Influenza Malaria Mental and neurological disorders Neglected tropical diseases Non-communicable diseases Pandemic Preparedness Public health implications of the implementation of the Nagoya Protocol Rare diseases Supply chain Sustainable development goals Tuberculosis Universal Health Coverage Vaccination confidence Vaccines innovation Vaccines protect communities Vaccines sustainability Value of immunization Viral hepatitis